{ "model": { "rank": 6418, "code": "thing-q210402", "model_id": "vr.tr.diazepam", "name": "diazepam", "purpose": "Enable an AI agent to recognise diazepam, assess the identity and usability of a particular material or medicinal presentation, and determine which handling or use actions require additional evidence or authority.", "family": "Thing Registry", "category": "Physical world and living systems", "status": "research-draft", "kind": "thing", "plane": "PHY", "domain": "PHY.OBJ", "industry": "", "version": "", "url": "/models/thing/q210402/", "tier": 2, "score": 60, "payload": { "layer": "wikidata", "aliases": [], "aliasCount": 0, "merged": 0, "knownIn": 60, "facets": null, "markers": [], "lexicalClass": "", "senseRank": null, "alsoRegisteredAs": "vr.tr.diazepam", "source": { "dataset": "wikidata", "item": "Q210402", "url": "https://www.wikidata.org/wiki/Q210402", "license": "CC0 1.0" } }, "research": { "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-07T14:22:49Z", "providers": [ "Codex", "Grok" ], "missingProviders": [], "pass": 2, "cost": { "grok": { "usd": 0.03819374, "turns": 2, "seconds": 141.4, "error": null }, "codex": { "seconds": 87.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.3\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a07c3d-eefe-7383-a875-140ad3ad0f00\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: diazepam\nRegistry id: vr.tr.diazepam\nPlane / domain: PHY / PHY.OBJ\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\nA Vercy" } } }, "metaModel": { "id": "THING-Q210402", "registryId": "vr.tr.diazepam", "name": "diazepam", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.OBJ" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q210402/", "model": { "registry_id": "vr.tr.diazepam", "name": "diazepam", "purpose": "Enable an AI agent to recognise diazepam, assess the identity and usability of a particular material or medicinal presentation, and determine which handling or use actions require additional evidence or authority.", "definition": "Diazepam is a long-acting 1,4-benzodiazepine (7-chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one) that positively modulates GABA-A receptors and is used as an anxiolytic, anticonvulsant, skeletal-muscle relaxant, and alcohol-withdrawal agent.", "scope_statement": "This model owns vr.tr.diazepam as a physical chemical substance, including the diazepam-specific properties and constraints needed to assess bulk material and diazepam-containing preparations, while linking to separate models for medicinal products, patients, prescriptions and administration events.", "in_scope": [ "Chemical identity and evidence distinguishing diazepam from other benzodiazepines, metabolites and unidentified material.", "Diazepam content, formulation and route compatibility of a represented sample or preparation.", "Quality, storage history and fitness for a stated pharmaceutical or analytical purpose.", "Diazepam-specific exposure, interaction and discontinuation constraints that require clinical review.", "Traceability and jurisdiction-dependent authority for possession, supply, administration and disposal." ], "out_of_scope": [ "Patient diagnosis, complete medical history and individual treatment selection.", "Prescription authorship, personalised dosing and taper design.", "Complete commercial product, packaging or delivery-device specifications.", "Manufacturing plant operations and detailed chemical synthesis procedures.", "Independent models of other benzodiazepines and diazepam metabolites.", "Full medication administration, emergency response and waste-management workflows." ], "distinguishing_features": [ "Require an explicit diazepam ingredient identity supported by a traceable product record or appropriate analytical evidence; a benzodiazepine class designation alone is insufficient.", "Distinguish diazepam from its metabolites and other benzodiazepines using substance-specific identification evidence rather than treating a class-level screening result as identification.", "Separate the diazepam substance from a branded preparation: an authenticated Valium product identifies a diazepam-containing product, not a different active substance. Reference: [DailyMed Valium label](https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=554baee5-b171-4452-a50a-41a0946f956c&type=display).", "Distinguish bulk diazepam from a finished preparation by recording its matrix, concentration and intended purpose; equal diazepam mass does not establish route compatibility.", "Treat tablet appearance, seller terminology and claimed calming effects as supporting observations rather than sufficient tests of diazepam identity." ], "characteristics": [ { "name": "Identity evidence", "kind": "state", "unit_or_values": "claimed | documentation-supported | analytically-supported | conflicting | unknown", "why_it_matters": "Determines whether the agent can identify the material as diazepam and with what evidential limits." }, { "name": "Material role", "kind": "category", "unit_or_values": "active pharmaceutical ingredient | finished medicinal preparation | analytical reference material | unidentified sample | other", "why_it_matters": "Prevents research material or bulk substance from being treated as a ready-to-administer medicine." }, { "name": "Preparation and authorised route", "kind": "relation", "unit_or_values": "Link to exact formulation, product label and permitted route or routes; unknown permitted", "why_it_matters": "Route and preparation govern handling and cannot be inferred from the active ingredient alone." }, { "name": "Diazepam amount or concentration", "kind": "measurement", "unit_or_values": "mg per unit, mg/mL or mass fraction, with denominator, method and labelled versus measured status", "why_it_matters": "Separates active substance quantity from total preparation mass, liquid volume and device contents." }, { "name": "Quality assessment", "kind": "state", "unit_or_values": "not assessed | meets named specification | fails named specification | inconclusive", "why_it_matters": "A quality judgement is meaningful only against an identified specification and intended use." }, { "name": "Storage and use-period status", "kind": "state", "unit_or_values": "within documented conditions | excursion awaiting assessment | expired | opening limit exceeded | history unknown", "why_it_matters": "Supports a decision to retain, quarantine or refer a preparation for assessment." }, { "name": "Batch and source traceability", "kind": "relation", "unit_or_values": "Links to manufacturer or supplier, batch, product identifier and supporting records", "why_it_matters": "Connects authenticity, quality findings and recalls to the actual material." }, { "name": "Exposure context", "kind": "relation", "unit_or_values": "Links to administered amount, route, time, repeated exposure and relevant co-exposures", "why_it_matters": "Allows clinical models to assess residual effects and interactions without interpreting package strength as patient exposure." }, { "name": "Action authorisation", "kind": "state", "unit_or_values": "verified for stated action | restricted | prohibited | unresolved, with jurisdiction and effective date", "why_it_matters": "Permission to possess a preparation does not establish permission to supply or administer it." } ], "affordances": [ "Reconcile a diazepam identity claim with product records, batch documentation and analytical findings.", "Compare labelled and measured diazepam content while preserving units and measurement uncertainty.", "Check whether a proposed handling or administration route matches the exact preparation and governing instructions.", "Flag storage excursions, quality failures, identity conflicts or applicable recalls for quarantine and review.", "Pass exposure and interaction concerns to an authorised clinical workflow with the supporting evidence.", "Check and record authority for transfer, dispensing or disposal under the applicable local rules." ] }, "sources": [ { "id": "wikipedia-diazepam", "title": "Diazepam", "url": "https://en.wikipedia.org/wiki/Diazepam", "what_it_supports": "Clinical uses, routes, legal scheduling by country, CAS/UNII/ATC/DrugBank identifiers, half-life ranges, WHO Essential Medicines listing, and FDA boxed-warning history.", "url_status": "live" }, { "id": "pubchem-3016", "title": "Diazepam | C16H13ClN2O | CID 3016", "url": "https://pubchem.ncbi.nlm.nih.gov/compound/Diazepam", "what_it_supports": "Molecular formula, PubChem CID, Wikidata Q210402, RxCUI, ATC N05BA01, MeSH synonyms including Valium, Diazemuls, Stesolid, Relanium and Seduxen, and GABA-A mechanism summary.", "url_status": "live" }, { "id": "statpearls-diazepam", "title": "Diazepam", "url": "https://www.ncbi.nlm.nih.gov/books/NBK537022/", "what_it_supports": "FDA-labelled indications (anxiety, muscle spasm/spasticity, preoperative anxiolysis, refractory epilepsy, status epilepticus), off-label ICU sedation, and GABA mechanism.", "url_status": "live" }, { "id": "dea-benzodiazepines", "title": "Benzodiazepines", "url": "https://www.deadiversion.usdoj.gov/drug_chem_info/Benzodiazepines.pdf", "what_it_supports": "US Schedule IV control of approved benzodiazepines, 2025 US dispensing volume for diazepam, and law-enforcement encounter counts.", "url_status": "live" }, { "id": "who-eeml-diazepam", "title": "Diazepam - WHO Model List of Essential Medicines", "url": "https://list.essentialmeds.org/recommendations/319", "what_it_supports": "INN, ATC N05BA01, core-list status, restriction of oral use to short-term emergency anxiety, and UN 1971 psychotropic Schedule IV classification.", "url_status": "live" }, { "id": "mayo-oral", "title": "Diazepam (oral route)", "url": "https://www.mayoclinic.org/drugs-supplements/diazepam-oral-route/description/drg-20072333", "what_it_supports": "Adult and paediatric oral dosing bands, branded oral products, and overdose/CNS-depressant interaction hazards.", "url_status": "blocked" }, { "id": "mayo-rectal", "title": "Diazepam (rectal route)", "url": "https://www.mayoclinic.org/drugs-supplements/diazepam-rectal-route/description/drg-20072190", "what_it_supports": "Rectal gel (Diastat) as a weight-based rescue treatment for seizure clusters.", "url_status": "blocked" }, { "id": "nhs-sps-benzo-equiv", "title": "Oral benzodiazepines and choosing equivalent doses", "url": "https://sps.nhs.uk/articles/oral-benzodiazepines-and-choosing-equivalent-doses/", "what_it_supports": "Diazepam as the oral equivalence reference, long-acting classification, licensed UK uses, and caution against accumulation in hepatic impairment.", "url_status": "live" }, { "id": "riss-2008", "title": "Benzodiazepines in epilepsy: pharmacology and pharmacokinetics", "url": "https://doi.org/10.1111/j.1600-0404.2008.01004.x", "what_it_supports": "Oral/rectal bioavailability, protein binding, parent and nordiazepam half-lives, and CYP-mediated metabolism to nordiazepam, temazepam and oxazepam.", "url_status": "blocked" }, { "id": "jat-designer-bzd", "title": "Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases", "url": "https://academic.oup.com/jat/article/47/1/1/6549532", "what_it_supports": "Therapeutic daily oral dose range, therapeutic plasma concentration band, onset, lipid solubility, and half-life used to separate diazepam from other benzodiazepines.", "url_status": "blocked" } ], "structure": { "bundles": [ { "id": "diazepam-identity", "name": "Diazepam identity", "description": "Establish what is being called diazepam and how that identity is supported.", "rationale": "A class name, brand claim or observed effect cannot establish the identity of the physical material.", "layers": [ { "id": "substance-boundary", "name": "Substance boundary", "description": "Separate diazepam itself from related substances and preparations containing it.", "findings": [ { "id": "identity-anchor", "name": "Identity anchor", "description": "Record the authoritative substance identity and the evidence connecting the represented material to it.", "questions": [ { "text": "Which authoritative chemical record defines the diazepam identity used here?", "kind": "definition", "id": "identity-anchor-q01" }, { "text": "Does this record represent diazepam substance, a diazepam-containing preparation or merely a claim about an unidentified sample?", "kind": "boundary", "id": "identity-anchor-q02" } ] } ] }, { "id": "identity-verification", "name": "Identity verification", "description": "Assess evidence that distinguishes diazepam from similar or substituted material.", "findings": [ { "id": "specificity-of-evidence", "name": "Specificity of evidence", "description": "Preserve what documentation or testing establishes, including unresolved mixtures and conflicting results.", "questions": [ { "text": "What authenticated product documentation or analytical result supports the diazepam claim?", "kind": "provenance", "id": "specificity-of-evidence-q01" }, { "text": "Can the identification method distinguish diazepam from other benzodiazepines and relevant metabolites in this sample matrix?", "kind": "measurement", "id": "specificity-of-evidence-q02" } ] } ] } ] }, { "id": "preparation-and-content", "name": "Preparation and content", "description": "Describe the physical presentation and the diazepam quantity available within it.", "rationale": "The active ingredient alone does not establish administration route, excipient suitability or delivered amount.", "layers": [ { "id": "formulation-route", "name": "Formulation and route", "description": "Connect the preparation to its specific route and composition constraints.", "findings": [ { "id": "route-compatibility", "name": "Route compatibility", "description": "Require preparation-specific evidence before accepting a route. An injection label, for example, specifies routes and excipients for that product. Reference: [DailyMed diazepam injection label](https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0813073-d0b0-4fd7-b307-56f69c910c82).", "questions": [ { "text": "Which routes does the exact diazepam preparation's current label permit?", "kind": "action", "id": "route-compatibility-q01" }, { "text": "Which excipients, sterility requirements or delivery-system features constrain the proposed use?", "kind": "boundary", "id": "route-compatibility-q02" } ] } ] }, { "id": "active-content", "name": "Active content", "description": "Distinguish labelled strength, measured content and deliverable quantity.", "findings": [ { "id": "quantity-basis", "name": "Quantity basis", "description": "Record diazepam quantity with a precise denominator and evidence, without treating it as a patient-specific dose.", "questions": [ { "text": "What is the labelled or measured diazepam amount per tablet, volume or delivery unit, and how was it established?", "kind": "measurement", "id": "quantity-basis-q01" }, { "text": "Does the stated quantity describe container contents, a selectable device setting or the amount actually delivered?", "kind": "boundary", "id": "quantity-basis-q02" } ] } ] } ] }, { "id": "quality-and-preservation", "name": "Quality and preservation", "description": "Assess whether the identified diazepam material remains suitable for its stated purpose.", "rationale": "Correct identity and nominal strength do not establish acceptable purity, integrity or storage history.", "layers": [ { "id": "quality-evidence", "name": "Quality evidence", "description": "Tie assessment to the material role, batch and applicable specification.", "findings": [ { "id": "fitness-for-purpose", "name": "Fitness for purpose", "description": "Separate identity confirmation from content, impurity and preparation-specific quality assessments.", "questions": [ { "text": "Which specification governs this diazepam material, and which batch-specific results support compliance?", "kind": "provenance", "id": "fitness-for-purpose-q01" }, { "text": "Which required tests of content, impurities or preparation integrity are missing, inconclusive or outside acceptance limits?", "kind": "measurement", "id": "fitness-for-purpose-q02" } ] } ] }, { "id": "storage-history", "name": "Storage history", "description": "Evaluate preservation against instructions for the actual formulation and container.", "findings": [ { "id": "continued-usability", "name": "Continued usability", "description": "Record expiry, opening or preparation events, container condition and excursions without inferring stability from appearance alone.", "questions": [ { "text": "What storage, light-protection and use-period instructions apply to this exact diazepam preparation?", "kind": "provenance", "id": "continued-usability-q01" }, { "text": "Does the documented history support continued use, or require quarantine and a product-specific stability assessment?", "kind": "action", "id": "continued-usability-q02" } ] } ] } ] }, { "id": "exposure-and-clinical-constraints", "name": "Exposure and clinical constraints", "description": "Represent the diazepam-specific information needed by a clinical decision-maker.", "rationale": "Safe decisions require exposure history and clinical context that cannot be derived from the physical preparation alone.", "layers": [ { "id": "exposure-persistence", "name": "Exposure persistence", "description": "Connect the material to time-dependent exposure assessment without assigning a universal duration of effect.", "findings": [ { "id": "residual-exposure-assessment", "name": "Residual exposure assessment", "description": "Require sourced interpretation of repeated administration, elimination and relevant metabolites before judging that prior exposure has ended.", "questions": [ { "text": "What amounts, routes and administration times are documented, including repeated exposure?", "kind": "provenance", "id": "residual-exposure-assessment-q01" }, { "text": "Which product pharmacology and patient-specific factors must the clinical model consider when assessing residual diazepam-related effects?", "kind": "boundary", "id": "residual-exposure-assessment-q02" } ] } ] }, { "id": "clinical-review-triggers", "name": "Clinical review triggers", "description": "Identify evidence that must accompany proposed initiation, continuation or discontinuation.", "findings": [ { "id": "interaction-and-withdrawal-review", "name": "Interaction and withdrawal review", "description": "Record review requirements for opioid or other CNS-depressant co-exposure and dependence or withdrawal concerns. Reference: [DailyMed diazepam tablet label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34ac0b9d-d4ad-4aaa-8bee-902365f4e9a8).", "questions": [ { "text": "Are relevant co-exposures, contraindications and precautions documented and reviewed against the exact product label?", "kind": "action", "id": "interaction-and-withdrawal-review-q01" }, { "text": "Does prior diazepam use require an authorised discontinuation or dose-reduction plan before the proposed change?", "kind": "action", "id": "interaction-and-withdrawal-review-q02" } ] } ] } ] }, { "id": "traceability-and-permitted-actions", "name": "Traceability and permitted actions", "description": "Connect the diazepam material to accountable custody and current authority for a proposed action.", "rationale": "Physical availability does not establish authenticity, supply eligibility or permission for clinical use.", "layers": [ { "id": "supply-traceability", "name": "Supply traceability", "description": "Maintain the evidence needed to investigate the provenance and disposition of a specific batch or package.", "findings": [ { "id": "authenticated-supply-record", "name": "Authenticated supply record", "description": "Link the material to manufacturer, supplier and batch evidence, preserving discrepancies for investigation.", "questions": [ { "text": "Can this diazepam package or bulk lot be traced to an authenticated supplier and matching batch record?", "kind": "provenance", "id": "authenticated-supply-record-q01" }, { "text": "Does a recall, packaging discrepancy or unexplained custody gap require withholding it from supply or use?", "kind": "action", "id": "authenticated-supply-record-q02" } ] } ] }, { "id": "action-specific-authority", "name": "Action-specific authority", "description": "Evaluate the proposed action under the applicable jurisdiction and institutional context.", "findings": [ { "id": "permission-evidence", "name": "Permission evidence", "description": "Record current diazepam control requirements and the actor's authority without assigning one legal status globally.", "questions": [ { "text": "Which current jurisdiction-specific requirements govern possession, transfer, dispensing, administration or disposal of this diazepam material?", "kind": "provenance", "id": "permission-evidence-q01" }, { "text": "What prescription, professional authority, custody record or disposal authorisation must be verified for the proposed action?", "kind": "action", "id": "permission-evidence-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-kinds", "name": "Kinds and varieties", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "oral scored tablets (typically 2 mg, 5 mg, 10 mg)", "oral solution and concentrated oral solution", "injectable solution in a propylene-glycol vehicle (intravenous or intramuscular)", "lipid-emulsion injection (Diazemuls-type)", "rectal gel or rectal tube for community seizure rescue", "intranasal spray for seizure clusters", "buccal film for paediatric seizure clusters" ], "questions": [ { "id": "evidence-kinds-q01", "text": "Which of these kinds and varieties hold for the sense of diazepam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "scheme": "INN", "value_or_pattern": "diazepam", "note": "WHO International Nonproprietary Name; USAN and BAN use the same stem." }, { "scheme": "CAS Registry Number", "value_or_pattern": "439-14-5", "note": "Parent compound." }, { "scheme": "PubChem CID", "value_or_pattern": "3016", "note": "NCBI PubChem compound record." }, { "scheme": "Wikidata", "value_or_pattern": "Q210402", "note": "Item for the chemical/drug." }, { "scheme": "UNII", "value_or_pattern": "Q3JTX2Q7TU", "note": "FDA Global Substance Registration System." }, { "scheme": "ATC", "value_or_pattern": "N05BA01", "note": "WHO ATC; veterinary counterpart QN05BA01." }, { "scheme": "DrugBank", "value_or_pattern": "DB00829", "note": "DrugBank accession." }, { "scheme": "RxNorm RXCUI", "value_or_pattern": "3322", "note": "NLM RxNorm ingredient." }, { "scheme": "ChEBI", "value_or_pattern": "CHEBI:49575", "note": "Chemical Entities of Biological Interest." }, { "scheme": "KEGG DRUG", "value_or_pattern": "D00293", "note": "KEGG drug entry." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of diazepam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "United Nations Convention on Psychotropic Substances (1971): Schedule IV, issued by the UN Commission on Narcotic Drugs / INCB.", "United States Controlled Substances Act: Schedule IV, enforced by DEA; FDA-approved benzodiazepines including diazepam are C-IV, while unapproved designer analogues are Schedule I.", "US FDA labelling: approved indications for anxiety, muscle spasm/spasticity, preoperative anxiolysis, and seizure adjunct/status epilepticus; class boxed warning (2020) for abuse, dependence and withdrawal.", "WHO Model List of Essential Medicines: diazepam is a core-list medicine (ATC N05BA01); oral use for anxiety is limited to short-term emergency management of acute severe symptoms.", "WHO mhGAP guideline (2023): strong recommendation against benzodiazepines for generalised anxiety or panic disorder in adults.", "National scheduling: US Schedule IV; Canada Schedule IV; UK Class C (CD POM); Australia S4 (prescription only); Germany prescription-only, Anlage III at higher doses; Brazil Class B1; Sweden Förteckning IV." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of diazepam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Oral tablets and solution prescribed for short-term severe anxiety, muscle spasm, alcohol-withdrawal symptom control, and as a taper/equivalence vehicle when switching benzodiazepines.", "Intravenous injection in emergency departments and intensive care for status epilepticus and acute agitation; intramuscular use is slower and less favoured than IV.", "Rectal gel (US Diastat/AcuDial) and rectal tubes (European Stesolid-type) issued to carers as out-of-hospital rescue for seizure clusters.", "Intranasal spray (US Valtoco) and buccal film used as alternative community rescue routes, especially where rectal administration is impractical.", "Procedural premedication for endoscopy, dentistry and surgery to provide anxiolysis, sedation and anterograde amnesia.", "Still widely dispensed but no longer the leading US benzodiazepine: IQVIA/DEA reported about 8.6 million US diazepam prescriptions in 2025, behind alprazolam, clonazepam and lorazepam." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of diazepam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "quantity": "usual oral tablet strength", "typical_range": "2-10", "unit": "mg" }, { "quantity": "adult oral anxiety dose", "typical_range": "2-10 mg, 2-4 times daily", "unit": "mg/day (commonly 4-40)" }, { "quantity": "parent-drug elimination half-life", "typical_range": "20-100 (often cited 21-70 or 24-48)", "unit": "h" }, { "quantity": "nordiazepam (desmethyldiazepam) half-life", "typical_range": "32-200 (often 49-179)", "unit": "h" }, { "quantity": "oral onset of action", "typical_range": "15-60", "unit": "min" }, { "quantity": "intravenous onset of action", "typical_range": "1-3", "unit": "min" }, { "quantity": "therapeutic plasma concentration", "typical_range": "0.1-2 (up to about 2.5)", "unit": "mg/L" }, { "quantity": "plasma protein binding", "typical_range": "96-99", "unit": "%" }, { "quantity": "oral benzodiazepine equivalence (reference dose)", "typical_range": "10", "unit": "mg oral diazepam" }, { "quantity": "injectable concentration", "typical_range": "5", "unit": "mg/mL" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of diazepam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Physical dependence, tolerance and withdrawal (including rebound anxiety, tremor and seizures) after more than brief use; abrupt stop after prolonged dosing is hazardous.", "Additive CNS and respiratory depression with alcohol, opioids and other sedatives; lone overdose is usually not fatal, combined overdose is.", "Falls, ataxia and cognitive impairment, especially in older adults.", "Accumulation of long-lived nordiazepam in hepatic impairment and in the elderly; NHS advice is not to switch patients with liver disease onto diazepam.", "Propylene-glycol vehicle in conventional IV solution: venous irritation/thrombophlebitis and, with prolonged infusion, glycol toxicity/lactic acidosis; lipid emulsion exists to avoid that vehicle.", "Loss of anticonvulsant effect if infused for more than about 24 hours.", "Paradoxical agitation or disinhibition in some patients.", "Neonatal hypotonia and withdrawal after late-pregnancy exposure.", "Diversion and illicit circulation; diazepam remains among benzodiazepines most often reported in US law-enforcement seizures, though volumes have fallen." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of diazepam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ "Brand naming: Valium is the historic global brand; Stesolid is common in Nordic/UK rectal-tube practice; Diastat and Valtoco are US rescue brands; Relanium (Poland), Seduxen/Sibazon (former Soviet practice), Faustan (German-speaking/Eastern Europe), Apaurin, and Diazemuls (UK/Canada emulsion injection) are local product names for the same INN.", "Seizure-rescue formulation: US practice centres on rectal gel (Diastat) and nasal spray (Valtoco); much of Europe uses rectal tubes (Stesolid) and increasingly buccal or nasal midazolam instead of rectal diazepam.", "Legal class is consistently a lower-schedule psychotropic (UN IV / US IV / UK Class C / AU S4) but the national schedule name and prescription-repeat rules differ.", "WHO essential-list policy now treats oral diazepam as emergency short-course anxiolysis only, while injectable diazepam remains an essential anticonvulsant option alongside midazolam." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of diazepam this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Reported by the breadth pass; each item needs checking against its source before it becomes normative.", "evidence": [ { "name": "lorazepam", "difference": "Lorazepam has no long-acting active metabolite and is cleared mainly by glucuronidation; diazepam is metabolised by CYP enzymes to nordiazepam, temazepam and oxazepam. In status epilepticus, IV lorazepam is often preferred because anticonvulsant effect outlasts diazepam's redistribution. Analytical separation is by LC-MS/GC-MS of parent drug and the nordiazepam/oxazepam/temazepam metabolite pattern unique to diazepam (and a few prodrugs)." }, { "name": "midazolam", "difference": "Midazolam is water-soluble, ultra-short-acting (half-life about 1-4 h) and preferred for IM/intranasal prehospital seizure rescue and procedural sedation; diazepam is highly lipophilic, long-acting, and poorly suited to the same IM kinetics. Identity is by structure (imidazole-benzodiazepine vs 1,4-benzodiazepin-2-one) and half-life." }, { "name": "clonazepam", "difference": "Clonazepam is a 7-nitro benzodiazepine used mainly as maintenance anticonvulsant/anxiolytic, without diazepam's nordiazepam metabolite chain; potency is higher (about 0.25 mg clonazepam ≈ 5 mg diazepam). Separate by nitro vs chloro substitution and metabolite panel (7-aminoclonazepam vs nordiazepam)." }, { "name": "alprazolam", "difference": "Alprazolam is a shorter-acting triazolobenzodiazepine used mainly for anxiety/panic and is the most dispensed US benzodiazepine; diazepam is longer-acting and still used for withdrawal, spasm and seizure rescue. Equivalent oral dose is about 0.5 mg alprazolam ≈ 10 mg diazepam; LC-MS distinguishes the triazolo core from diazepam." }, { "name": "chlordiazepoxide", "difference": "Both are long-acting and used in alcohol withdrawal; chlordiazepoxide is an N-oxide 1,4-benzodiazepine (Librium class) that also feeds nordiazepam. Distinguish by parent-drug assay and by the absence of diazepam as the administered molecule." }, { "name": "nordiazepam (desmethyldiazepam)", "difference": "Nordiazepam is diazepam's major active metabolite and a marketed drug in some countries; a finding of nordiazepam plus oxazepam/temazepam without parent diazepam may reflect nordiazepam dosing or late sampling after diazepam. Timing plus parent-drug detection separates them." }, { "name": "diclazepam (2'-chloro-diazepam)", "difference": "A designer analogue that metabolises to delorazepam/lorazepam-related products; it is not an FDA-approved medicine and in the US falls with other designer benzodiazepines under Schedule I, whereas diazepam is Schedule IV. Separate by the extra aromatic chlorine and the metabolite profile." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of diazepam this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does an existing Vercy world model already own diazepam or a concept boundary that requires this registry entry to link to it?", "Which authoritative substance identifiers and analytical standards should anchor diazepam identification across pharmaceutical and non-pharmaceutical samples?", "Which formulations, delivery systems and human or veterinary contexts must the model support in its intended jurisdictions?", "Which product-specific quality, compatibility and storage-excursion evidence is sufficient to determine usability for each supported preparation?", "Which current local control rules and clinical escalation protocols should be linked, and who is responsible for keeping them current?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 28 } }, "draft": { "generator": "vr.draft.v3", "status": "draft-generated", "researched": false, "archetype": "device, machine or tool", "method": "Written from the archetype playbook - what this kind of thing needs beyond identity and provenance - and from the structure that recurred across 6,333 models already researched by two engines. Applied to this entry by rule. No source was read for this thing and no claim here is researched. This entry carries no facets of its own, so they were inferred from its domain - a guess about a whole domain applied to one thing.", "facetsInferred": true, "nextPass": "A researcher replaces this draft with a sourced specification. Treat every sentence below as a proposal to argue with.", "purpose": "Give an agent a durable, checkable way to recognise a diazepam, record what state it is in, and decide what may be done with it.", "whatItIs": "Enable an AI agent to recognise diazepam, assess the identity and usability of a particular material or medicinal presentation, and determine which handling or use actions require additional evidence or authority.", "characteristics": { "substance": "material", "origin": "manufactured", "agency": "inert", "mobility": "varies" }, "whatYouCanDoWithIt": [ "observed and measured" ], "distinguishingFeatures": [ "Described in 60 Wikipedia languages, which is a measure of how widely the thing is known, not of how important it is." ], "openQuestionsForResearch": [ "Which of the bundles below does a real task actually need, and which are ceremony?", "What does this thing have that the facets do not capture at all?", "Which neighbouring kind is most often confused with a diazepam, and on what evidence are they told apart?" ], "whatItIsMadeOf": "matter you can touch", "physicalCharacter": [ "Mobility varies between examples.", "Does nothing on its own; everything it does, something else did to it.", "These come from the domain this entry sits in rather than from the entry itself, so treat them as a first guess about the whole domain applied to one thing." ], "whatCanBeDoneWithIt": [ "observe it, measure it, record its state" ], "howItIsRecognised": [ "Recognised by form, by the arrangement of its controls, and by markings - a plate, a model number, a certification mark. Form alone rarely separates two models that do very different things." ], "relatedModels": [], "standing": "Described in 60 Wikipedia languages, which measures how widely it is written about rather than how important or how common it is.", "structure": { "bundles": [ { "id": "identity-and-classification", "name": "Identity, naming and classification", "description": "How an agent tells one diazepam from another, and a diazepam from things that resemble it.", "rationale": "Recognition comes before every other claim. Without stable identity nothing else in the model can be trusted to be about the same thing twice.", "layers": [ { "id": "naming-and-identifiers", "name": "Names and identifiers", "description": "The names this thing goes by and the identifiers that survive translation and time.", "findings": [ { "id": "preferred-name-and-aliases", "name": "Preferred name, aliases and local names", "description": "Which name to use, which names mean the same thing, and which merely sound similar.", "questions": [ { "id": "preferred-name-and-aliases-q01", "text": "What identifies and describes the name of a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "preferred-name-and-aliases-q02", "text": "Who or what asserted this about the name of a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "preferred-name-and-aliases-q03", "text": "What may an agent decide or do once the name of a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "stable-identifiers", "name": "Stable identifiers and external keys", "description": "Identifiers that keep pointing at this kind of thing across systems and languages.", "questions": [ { "id": "stable-identifiers-q01", "text": "What identifies and describes an identifier for a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stable-identifiers-q02", "text": "Who or what asserted this about an identifier for a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stable-identifiers-q03", "text": "What may an agent decide or do once an identifier for a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "classification-and-granularity", "name": "Classification and granularity", "description": "Where a diazepam sits among kinds, and how finely a task needs to cut it.", "findings": [ { "id": "kind-and-parents", "name": "Kind, parents and neighbouring kinds", "description": "The classes this thing belongs to and the ones it is next to.", "questions": [ { "id": "kind-and-parents-q01", "text": "What identifies and describes the kind of a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "kind-and-parents-q02", "text": "Who or what asserted this about the kind of a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "kind-and-parents-q03", "text": "What may an agent decide or do once the kind of a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] }, { "id": "distinguishing-features", "name": "Distinguishing features", "description": "What separates a diazepam from the things most often confused with it.", "questions": [ { "id": "distinguishing-features-q01", "text": "What identifies and describes what distinguishes a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "distinguishing-features-q02", "text": "Who or what asserted this about what distinguishes a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "distinguishing-features-q03", "text": "What may an agent decide or do once what distinguishes a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "form-and-composition", "name": "Form, composition and condition", "description": "What a diazepam is made of, what shape and size it takes, and what state it is in.", "rationale": "A physical thing can be measured, and a model that cannot record its measurements cannot support any decision that depends on them.", "layers": [ { "id": "form-and-dimensions", "name": "Form and dimensions", "description": "Shape, size, mass and the ranges these take across examples.", "findings": [ { "id": "measurable-dimensions", "name": "Measurable dimensions and their units", "description": "The quantities worth recording and the units they are recorded in.", "questions": [ { "id": "measurable-dimensions-q01", "text": "What identifies and describes the dimensions of a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "measurable-dimensions-q02", "text": "Who or what asserted this about the dimensions of a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "measurable-dimensions-q03", "text": "What may an agent decide or do once the dimensions of a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "material-and-composition", "name": "Material and composition", "description": "Materials, parts and how they are put together.", "findings": [ { "id": "parts-and-materials", "name": "Parts and materials", "description": "What a diazepam is built from and which parts are replaceable.", "questions": [ { "id": "parts-and-materials-q01", "text": "What identifies and describes the composition of a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "parts-and-materials-q02", "text": "Who or what asserted this about the composition of a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "parts-and-materials-q03", "text": "What may an agent decide or do once the composition of a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "condition-and-integrity", "name": "Condition and integrity", "description": "Wear, damage, health and the difference between working and broken.", "findings": [ { "id": "condition-assessment", "name": "Condition, damage and health", "description": "How the condition of a diazepam is judged and by whom.", "questions": [ { "id": "condition-assessment-q01", "text": "What identifies and describes the condition of a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "condition-assessment-q02", "text": "Who or what asserted this about the condition of a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "condition-assessment-q03", "text": "What may an agent decide or do once the condition of a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "place-and-movement", "name": "Place and movement", "description": "Where a diazepam is, how it got there and where it may go (varies).", "rationale": "A thing that can move needs its position recorded with a time, or every later claim about it is about a place it has left.", "layers": [ { "id": "location-and-placement", "name": "Location and placement", "description": "Position, containment and the reference frame the position is given in.", "findings": [ { "id": "position-and-frame", "name": "Position, container and reference frame", "description": "Where a diazepam is, and what that position is measured against.", "questions": [ { "id": "position-and-frame-q01", "text": "What identifies and describes the location of a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "position-and-frame-q02", "text": "Who or what asserted this about the location of a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "position-and-frame-q03", "text": "What may an agent decide or do once the location of a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "movement-and-transfer", "name": "Movement and transfer", "description": "How a diazepam is carried, installed or relocated.", "findings": [ { "id": "movement-events", "name": "Movement events and constraints", "description": "What counts as a movement, what records it and what limits it.", "questions": [ { "id": "movement-events-q01", "text": "What identifies and describes the movement of a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "movement-events-q02", "text": "Who or what asserted this about the movement of a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "movement-events-q03", "text": "What may an agent decide or do once the movement of a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "state-and-lifecycle", "name": "State and lifecycle", "description": "The states a diazepam passes through and the events that move it between them.", "rationale": "Most decisions about a thing depend on what state it is in now, which is a claim with a time on it, not a property.", "layers": [ { "id": "lifecycle-stages", "name": "Lifecycle stages", "description": "From coming into existence to ceasing to be one of these.", "findings": [ { "id": "stages-and-transitions", "name": "Stages and transitions", "description": "The stages worth naming and what moves a diazepam between them.", "questions": [ { "id": "stages-and-transitions-q01", "text": "What identifies and describes the lifecycle of a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "stages-and-transitions-q02", "text": "Who or what asserted this about the lifecycle of a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "stages-and-transitions-q03", "text": "What may an agent decide or do once the lifecycle of a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "observations-and-status", "name": "Observations and current status", "description": "What is observed about a diazepam, how often and by whom.", "findings": [ { "id": "observation-record", "name": "Observation record", "description": "How an observation of a diazepam is recorded so that it can be superseded rather than overwritten.", "questions": [ { "id": "observation-record-q01", "text": "What identifies and describes an observation of a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "observation-record-q02", "text": "Who or what asserted this about an observation of a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "observation-record-q03", "text": "What may an agent decide or do once an observation of a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] }, { "id": "function-and-principle", "name": "Function and operating principle", "description": "What diazepam is for and how it achieves it.", "rationale": "Two devices with the same name can work on different principles, and the principle is what predicts failure and constrains use.", "layers": [ { "id": "intended-function", "name": "Intended function", "description": "The job it does, and the jobs it is used for anyway.", "findings": [ { "id": "function-record", "name": "Function, principle and variants", "description": "What it does, how, and which variants do it differently.", "questions": [ { "id": "function-record-q01", "text": "What function does diazepam perform, on what operating principle, and which variants differ in that principle?", "kind": "definition" }, { "id": "function-record-q02", "text": "What use falls outside the intended function but happens in practice?", "kind": "boundary" } ] } ] }, { "id": "capacity-and-rating", "name": "Capacity and rating", "description": "The numbers that say what it can do and where it stops.", "findings": [ { "id": "ratings", "name": "Ratings and their conditions", "description": "Rated capacity, power, throughput and the conditions each assumes.", "questions": [ { "id": "ratings-q01", "text": "What ratings characterise diazepam, in what units, and under what stated conditions?", "kind": "measurement" }, { "id": "ratings-q02", "text": "What happens beyond the rating - degradation, refusal, damage - and how is that detected?", "kind": "action" } ] } ] } ] }, { "id": "operation-and-state", "name": "Operation, controls and state", "description": "How diazepam is operated and what state it is in right now.", "rationale": "An agent acting on a device needs its current state and the controls that change it, not just its specification.", "layers": [ { "id": "controls-and-modes", "name": "Controls and modes", "description": "What can be set, what that changes, and what is interlocked.", "findings": [ { "id": "control-surface", "name": "Control surface and interlocks", "description": "The settings available and the conditions that block them.", "questions": [ { "id": "control-surface-q01", "text": "What controls and modes does diazepam have, and what does each change?", "kind": "definition" }, { "id": "control-surface-q02", "text": "Which actions are interlocked or forbidden in which state, and what must be true before acting?", "kind": "action" } ] } ] }, { "id": "condition-and-maintenance", "name": "Condition and maintenance", "description": "Wear, service intervals, consumables and the line between working and broken.", "findings": [ { "id": "service-record", "name": "Condition, service and consumables", "description": "What is consumed, what is serviced, and how condition is judged.", "questions": [ { "id": "service-record-q01", "text": "What consumables and service does diazepam need, at what interval, and on whose authority?", "kind": "measurement" }, { "id": "service-record-q02", "text": "What evidence separates a unit that is working from one that is out of service?", "kind": "boundary" } ] } ] } ] }, { "id": "kind-model-unit", "name": "Kind, model and unit", "description": "Whether a claim about diazepam is about the kind, a product line, or one physical unit.", "rationale": "This is the boundary most often got wrong for made things, and getting it wrong mixes a catalogue entry with the machine in the yard.", "layers": [ { "id": "level-of-reference", "name": "Level of reference", "description": "The three levels and what belongs at each.", "findings": [ { "id": "level-rules", "name": "What belongs to kind, model and unit", "description": "Which properties are shared by all of them and which are not.", "questions": [ { "id": "level-rules-q01", "text": "Which facts about diazepam hold for every one of them, which for a model, and which only for one unit?", "kind": "boundary" }, { "id": "level-rules-q02", "text": "What identifies an individual unit, and what should an agent do when it has only the kind?", "kind": "action" } ] } ] }, { "id": "standards-and-conformity", "name": "Standards and conformity", "description": "The standards a working example must meet and who attests it.", "findings": [ { "id": "conformity", "name": "Standards, marks and attestation", "description": "Which standard applies, who certifies, and what the mark means.", "questions": [ { "id": "conformity-q01", "text": "Which standards govern diazepam, issued by whom, and what does conformity actually assert?", "kind": "provenance" }, { "id": "conformity-q02", "text": "What may an agent conclude from a certification mark, and what may it not?", "kind": "boundary" } ] } ] } ] }, { "id": "provenance-and-evidence", "name": "Provenance, evidence and time", "description": "Where every claim about a diazepam came from and when it held.", "rationale": "A claim without a source and a time cannot be superseded, only overwritten, and an agent that overwrites loses the ability to explain itself.", "layers": [ { "id": "source-and-authority", "name": "Source and authority", "description": "Who said it, on what evidence, and how strongly.", "findings": [ { "id": "claim-provenance", "name": "Claim provenance and confidence", "description": "The authority behind each claim about a diazepam and how confident it is.", "questions": [ { "id": "claim-provenance-q01", "text": "What identifies and describes a claim about a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "claim-provenance-q02", "text": "Who or what asserted this about a claim about a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "claim-provenance-q03", "text": "What may an agent decide or do once a claim about a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] }, { "id": "time-and-versions", "name": "Time, versions and supersession", "description": "When a claim was true, when it was learnt, and what replaced it.", "findings": [ { "id": "validity-and-supersession", "name": "Validity period and supersession", "description": "How an old claim about a diazepam is retired without being erased.", "questions": [ { "id": "validity-and-supersession-q01", "text": "What identifies and describes the validity of a claim about a diazepam, and in what units or vocabulary?", "kind": "definition", "answer_data": [ "identifiers", "types and classes", "values with units", "explicit unknowns" ] }, { "id": "validity-and-supersession-q02", "text": "Who or what asserted this about the validity of a claim about a diazepam, by which method, and when was it true?", "kind": "provenance", "answer_data": [ "authority", "method", "evidence", "event time", "knowledge time" ] }, { "id": "validity-and-supersession-q03", "text": "What may an agent decide or do once the validity of a claim about a diazepam is known, and what must it refuse?", "kind": "action", "answer_data": [ "permitted actions", "preconditions", "refusals", "escalation" ] } ] } ] } ] } ] }, "statistics": { "bundles": 8, "layers": 17, "findings": 19, "questions": 51 } } } }